Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation

Immunology Letters

Volumn 138, Issue 2, 2011, Pages 144-155

  Shen, Chuanlai ^a   He, Yong ^a   Cheng, Kai ^a   Zhang, Daoping ^a   Miao, Shenwei ^a   Zhang, Aifeng ^a   Meng, Fanyan ^a   Miao, Fengqin ^a   Zhang, Jianqiong ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Alloreactive T cells; Apoptosis; Killer antigen presenting cells; Transplantation

Indexed keywords

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; ARTIFICIAL CELL; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; GROWTH INHIBITION; KILLER CELL; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TRANSPLANTATION; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; APOPTOSIS; ARTIFICIAL CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FAS LIGAND PROTEIN; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; LYMPHOCYTE DEPLETION; MAGNETICS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSPHERES; MODELS, ANIMAL; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959560116     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.04.002     Document Type: Article

References (39)

1. Matsue H., Matsue K., Walters M., Okumura K., Yagita H., Takashima A. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999, 5:930-937.
2. Matsue H., Matsue K., Kusuhara M., Kumamoto T., Okumura K., Yagita H., et al. Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 2001, 98:3465-3472.
3. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002, 17:795-808.
4. Whartenby K.A., Straley E.E., Kim H., Racke F., Tanavde V., Gorski K.S., et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002, 100:3147-3154.
5. Kusuhara M., Matsue K., Edelbaum D., Loftus J., Takashima A., Matsue H. Killing of naive T cells by CD95L-transfected dendritic cells (DC): in vivo study using killer DC-DC hybrids and CD4(+) T cells from DO11.10 mice. Eur J Immunol 2002, 32:1035-1043.
6. Hoves S., Krause S.W., Halbritter D., Zhang H.G., Mountz J.D., Scholmerich J., et al. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol 2003, 170:5406-5413.
7. Buonocore S., Flamand V., Claessen N., Heeringa P., Goldman M., Florquin S. Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice. Clin Exp Immunol 2004, 137:74-80.
8. Strauss G., Osen W., Knape I., Jacobsen E.M., Muller S.M., Debatin K.M. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity. Cell Death Differ 2007, 14:480-488.
9. Schutz C., Fleck M., Mackensen A., Zoso A., Halbritter D., Schneck J.P., et al. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood 2008, 111:3546-3552.
10. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
11. Buonocore S., Paulart F., Le Moine A., Braun M., Salmon I., Van Meirvenne S., et al. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 2003, 101:1469-1476.
12. Hermans I.F., Ritchie D.S., Yang J., Roberts J.M., Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000, 164:3095-3101.
13. Shen C., Chang C.C., Zhang J., Guo W., Xia L., Meng F., et al. Structural and functional characterization of peptide-beta2m fused HLA-A2/MART1(27-35) complexes. Biochem Biophys Res Commun 2006, 342:57-65.
14. Shen C., Zhang J., Xia L., Meng F., Xie W. Induction of tumor antigen-specific cytotoxic T cell responses in naive mice by latex microspheres-based artificial antigen-presenting cell constructs. Cell Immunol 2007, 247:28-35.
15. Meng F., Shen C., He Y., Miao F., Zhang J. Cloning and expression of three peptide-linked beta2-microglobulin molecules in Escherichia coli with an isocaudamer technique. Biotechnol Lett 2009, 31:831-836.
16. Rosenberg A.S. Skin allograft rejection. Curr Protoc Immunol 2001, [chapter 4: unit 4.4].
17. Kuhns S.T., Pease L.R. A region of conformational variability outside the peptide-binding site of a class I MHC molecule. J Immunol 1998, 161:6745-6750.
18. Caballero A., Fernandez N., Lavado R., Bravo M.J., Miranda J.M., Alonso A. Tolerogenic response: allorecognition pathways. Transpl Immunol 2006, 17:3-6.
19. Kappel B.J., Pinilla-Ibarz J., Kochman A.A., Eng J.M., Hubbard V.M., Leiner I., et al. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood 2006, 107:2045-2051.
20. Wu B., Wu J.M., Miagkov A., Adams R.N., Levitsky H.I., Drachman D.B. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J Immunol 2001, 166:4773-4779.
21. Fleck M., Zhang H.G., Kern E.R., Hsu H.C., Muller-Ladner U., Mountz J.D. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum 2001, 44:964-973.
22. Zhang H.G., Fleck M., Kern E.R., Liu D., Wang Y., Hsu H.C., et al. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest 2000, 105:813-821.
23. Wolfe T., Asseman C., Hughes A., Matsue H., Takashima A., von Herrath M.G. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol 2002, 169:4867-4872.
24. Matsumoto Y., Fujita T., Hirai I., Sahara H., Torigoe T., Ezoe K., et al. Immunosuppressive effect on T cell activation by interleukin-16- and interleukin-10-cDNA-double-transfected human squamous cell line. Burns 2009, 35:383-389.
25. Faust S.M., Lu G., Marini B.L., Zou W., Gordon D., Iwakura Y., et al. Role of T cell TGF beta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol 2009, 183:7297-7306.
26. Orbach A., Rachmilewitz J., Parnas M., Huang J.H., Tykocinski M.L., Dranitzki-Elhalel M. CTLA-4. FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol 2007, 179:7287-7294.
27. Ierino F.L., Mulley W., Dodge N., Li Y.Q., Mouhtouris E., Christiansen D., et al. Dendritic cells expressing soluble CTLA4Ig prolong antigen-specific skin graft survival. Immunol Cell Biol 2010, 58. 10.1038/icb.2010.
28. Mitchell M.S., Kan-Mitchell J., Morrow P.R., Darrah D., Jones V.E., Mescher M.F. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004, 10:76-83.
29. Goldberg J., Shrikant P., Mescher M.F. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003, 170:228-235.
30. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., Schneck J.P. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003, 9:619-624.
31. Oosten L.E., Blokland E., van Halteren A.G., Curtsinger J., Mescher M.F., Falkenburg J.H., et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 2004, 104:224-226.
32. Schilbach K., Kerst G., Walter S., Eyrich M., Wernet D., Handgretinger R., et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 2005, 106:144-149.
33. Hippen K.L., Harker-Murray P., Porter S.B., Merkel S.C., Londer A., Taylor D.K., et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008, 112:2847-2857.
34. Lu X.L., Jiang X.B., Liu R.E., Zhang S.M., Liang Z.H. In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells. Cancer Immunol Immunother 2009, 58:629-638.
35. Ugel S., Zoso A., De Santo C., Li Y., Marigo I., Zanovello P., et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res 2009, 69:9376-9384.
36. Yuan R.R., Wong P., McDevitt M.R., Doubrovina E., Leiner I., Bornmann W., et al. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood 2004, 104:2397-2402.
37. Hess P.R., Barnes C., Woolard M.D., Johnson M.D., Cullen J.M., Collins E.J., et al. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 2007, 109:3300-3307.
38. Tanriver Y., Ratnasothy K., Bucy R.P., Lombardi G., Lechler R. Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J Immunol 2010, 184:1757-1764.
39. Askenasy N., Yolcu E.S., Yaniv I., Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2005, 105:1396-1404.